Physician profile

William G Stone

Surgery · Sonora, CA

NPI 1255505764

$255.32

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$88.94

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Mdd US Operations, LLC $88.94 2024 Gocovri
Smith+Nephew, INC. $39.07 2020-2021
Teleflex LLC $20.20 2021
Merck Sharp & Dohme LLC $15.62 2019
Janssen Biotech, INC. $15.60 2019
Celgene Corporation $14.36 2019
Olympus America INC. $13.54 2019
Takeda Pharmaceuticals U.S.A., INC. $13.05 2019
Octapharma USA, INC. $12.05 2019
Pharmacyclics LLC, An Abbvie Company $11.46 2019
Incyte Corporation $11.43 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

William G Stone

$255.32

in general payments reported 2019-2025

Years
2019-2024
Top company
Mdd US Operations, LLC

https://glasscript.com/doctor/1111171/william-g-stone

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.